These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8072437)

  • 21. Estrogen and SERM neuroprotection in animal models of Parkinson's disease.
    Morissette M; Al Sweidi S; Callier S; Di Paolo T
    Mol Cell Endocrinol; 2008 Aug; 290(1-2):60-9. PubMed ID: 18515001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson's disease: A contribution to sex-specific neuroprotection by estrogens.
    Gillies GE; McArthur S
    Horm Behav; 2010 Jan; 57(1):23-34. PubMed ID: 19538962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.
    Hornstein MD; Surrey ES; Weisberg GW; Casino LA
    Obstet Gynecol; 1998 Jan; 91(1):16-24. PubMed ID: 9464714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parkinson's disease, depression, and ECT: a review and case study.
    Asnis G
    Am J Psychiatry; 1977 Feb; 134(2):191-5. PubMed ID: 835744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sex differences in Parkinson's disease and other movement disorders.
    Smith KM; Dahodwala N
    Exp Neurol; 2014 Sep; 259():44-56. PubMed ID: 24681088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obesity and GnRH action. Report of a case with contribution by peripherally derived estrogens.
    Hansen LM; Batzer FR; Corson SL; Bello S
    J Reprod Med; 1997 Apr; 42(4):247-50. PubMed ID: 9131500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical predictive factors of subthalamic stimulation in Parkinson's disease.
    Welter ML; Houeto JL; Tezenas du Montcel S; Mesnage V; Bonnet AM; Pillon B; Arnulf I; Pidoux B; Dormont D; Cornu P; Agid Y
    Brain; 2002 Mar; 125(Pt 3):575-83. PubMed ID: 11872614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New biochemical and molecular aspects of estrogen's action].
    Teppa Garrán AD; Terán Dávila J
    Ginecol Obstet Mex; 2005 Aug; 73(8):436-42. PubMed ID: 16304969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia.
    Haleem DJ
    Behav Pharmacol; 2015 Feb; 26(1-2):45-58. PubMed ID: 25503261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacotherapy of Parkinson's disease.
    Cohen MM; Scheife RT
    Am J Hosp Pharm; 1977 May; 34(5):531-8. PubMed ID: 326045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implications for estrogens in Parkinson's disease: an epidemiological approach.
    Ragonese P; D'Amelio M; Savettieri G
    Ann N Y Acad Sci; 2006 Nov; 1089():373-82. PubMed ID: 17261781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease.
    Khakimova GR; Kozina EA; Kucheryanu VG; Ugrumov MV
    Mol Neurobiol; 2017 Jul; 54(5):3618-3632. PubMed ID: 27194433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of depression and parkinsonism during ECT: a case study.
    Dysken M; Evans HM; Chan CH; Davis JM
    Neuropsychobiology; 1976; 2(2-3):81-6. PubMed ID: 1012451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome.
    Mezrow G; Shoupe D; Spicer D; Lobo R; Leung B; Pike M
    Fertil Steril; 1994 Nov; 62(5):932-7. PubMed ID: 7926137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The role of estrogens in Parkinson's disease].
    Dziedziejko V; Białecka M; Machoy-Mokrzyńska A; Kłodowska-Duda G; Chlubek D
    Postepy Hig Med Dosw (Online); 2009 Dec; 63():627-33. PubMed ID: 20097949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogens and Parkinson disease: neuroprotective, symptomatic, neither, or both?
    Saunders-Pullman R
    Endocrine; 2003 Jun; 21(1):81-7. PubMed ID: 12777707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implication of the subthalamic nucleus in the pathophysiology and pathogenesis of Parkinson's disease.
    Benazzouz A; Piallat B; Ni ZG; Koudsie A; Pollak P; Benabid AL
    Cell Transplant; 2000; 9(2):215-21. PubMed ID: 10811394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain neurotransmitters and neuropeptides in Parkinson's disease.
    Rinne UK; Rinne JO; Rinne JK; Laakso K; Lönnberg P
    Acta Physiol Pharmacol Latinoam; 1984; 34(3):287-99. PubMed ID: 6099688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A case of Parkinson's disease following dystonia].
    Yasuda C; Takei T; Uozumi T; Toyota T; Yuhi T; Adachi H
    Rinsho Shinkeigaku; 2016 Sep; 56(9):600-4. PubMed ID: 27498816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients.
    Boccardo F; Rubagotti A; Amoroso D; Agostara B; Amadori D; Gallo L; Iacobelli S; Massidda B; Mesiti M; Pacini P; Tomao S; Paganuzzi M; Marroni P
    Cancer Chemother Pharmacol; 1999; 43(6):461-6. PubMed ID: 10321505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.